Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer

This study is examining whether the race or ethnicity of a patient affects how well a hormone-blocking drug called abiraterone (combined with prednisone) works for men with prostate cancer that has spread (metastatic) and is being treated with hormone therapy for the first time. **You may be eligible if...** - You are a man with prostate cancer confirmed by biopsy or cytology - Your cancer has spread to soft tissue or bone (metastatic disease) - You have started hormone therapy (medical or surgical castration) no more than 42 days ago - You are willing to take abiraterone plus prednisone as part of your treatment - You have had recent imaging (bone scan or PET scan within 42 days) **You may NOT be eligible if...** - You have been on hormone therapy (castration) for more than 42 days for metastatic prostate cancer - You are not willing to continue or start hormone therapy alongside abiraterone - Your cancer has not been confirmed as metastatic - You have significant health conditions that prevent participation Talk to your doctor to see if this trial is right for you.